Compare UIS & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UIS | MDXH |
|---|---|---|
| Founded | 1942 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 183.4M |
| IPO Year | 1994 | 2021 |
| Metric | UIS | MDXH |
|---|---|---|
| Price | $2.28 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.67 | ★ $7.67 |
| AVG Volume (30 Days) | ★ 897.1K | 103.1K |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,950,100,000.00 | N/A |
| Revenue This Year | N/A | $30.31 |
| Revenue Next Year | $2.60 | $18.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.11 | $1.36 |
| 52 Week High | $5.33 | $5.33 |
| Indicator | UIS | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 45.06 |
| Support Level | $2.11 | $3.05 |
| Resistance Level | $2.65 | $3.78 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 17.86 | 22.73 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.